Literature DB >> 33661467

Comorbid insomnia and sleep apnea: characterization of the syndrome and understanding its associations with comorbid sleep conditions.

Shyam Subramanian1, Sean E Hesselbacher2,3, Phillip Nye4, Akshar A Aiyer5, Salim R Surani5,6.   

Abstract

PURPOSE: Obstructive sleep apnea (OSA) is traditionally associated with excessive daytime sleepiness. Insomnia is characterized by hyperarousal, and is seen as a predominant feature in a subgroup of patients with OSA. The aim of this study was to describe the prevalence of comorbid insomnia and sleep apnea (COMISA) in a sleep apnea population and to characterize its features.
METHODS: This was a chart review of patients who underwent overnight polysomnography (PSG). All patients completed questionnaires with the Epworth Sleepiness Scale (ESS), and symptoms of insomnia and other sleep-related comorbidities. Patients with OSA on the PSG were included.
RESULTS: A total of 296 patients with OSA were included, of which 80% reported at least 1 major symptom of insomnia: 57% reported sleep onset insomnia, 68% sleep maintenance insomnia, and 48% had early morning awakenings. COMISA (OSA plus 2 or more major symptoms of insomnia) was seen in 63%. These patients were more likely to report an abnormal ESS score, gastroesophageal reflux (GER), and restless legs (RL) than those without; no difference was seen in self-reported sleep bruxism. Among the patients with COMISA, 85% reported at least 1 representative symptom of psychophysiological insomnia (PPI); each of the 5 PPI symptoms was present in at least 40% of patients with COMISA.
CONCLUSIONS: Insomnia is extremely prevalent in our population of patients with OSA, accompanied by daytime sleepiness and symptoms of PPI, GER, and RL. Further study is needed to determine the interactions between symptoms and OSA treatments in these patients.
© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Keywords:  Insomnia; Obstructive sleep apnea; Syndrome

Mesh:

Year:  2021        PMID: 33661467     DOI: 10.1007/s11325-021-02331-1

Source DB:  PubMed          Journal:  Sleep Breath        ISSN: 1520-9512            Impact factor:   2.816


  11 in total

Review 1.  Insomnia: definition, prevalence, etiology, and consequences.

Authors:  Thomas Roth
Journal:  J Clin Sleep Med       Date:  2007-08-15       Impact factor: 4.062

2.  Gender differences in the effect of comorbid insomnia symptom on depression, anxiety, fatigue, and daytime sleepiness in patients with obstructive sleep apnea.

Authors:  Min-hwan Lee; Sang-Ahm Lee; Gha-hyun Lee; Ho-Sung Ryu; Seockhoon Chung; Yoo-Sam Chung; Woo Sung Kim
Journal:  Sleep Breath       Date:  2013-05-09       Impact factor: 2.816

3.  Fifty Years of Physiology in Obstructive Sleep Apnea.

Authors:  Magdy Younes
Journal:  Am J Respir Crit Care Med       Date:  2017-10-15       Impact factor: 21.405

4.  Prevalence of excessive sleepiness is higher whereas insomnia is lower with greater severity of obstructive sleep apnea.

Authors:  Bjørn Bjorvatn; Sverre Lehmann; Shashi Gulati; Harald Aurlien; Ståle Pallesen; Ingvild W Saxvig
Journal:  Sleep Breath       Date:  2015-04-09       Impact factor: 2.816

5.  Insomnia complaints in patients evaluated for obstructive sleep apnea.

Authors:  Suzanne B Krell; Vishesh K Kapur
Journal:  Sleep Breath       Date:  2005-09       Impact factor: 2.816

6.  Prevalence of insomnia symptoms in patients with sleep-disordered breathing.

Authors:  B Krakow; D Melendrez; E Ferreira; J Clark; T D Warner; B Sisley; D Sklar
Journal:  Chest       Date:  2001-12       Impact factor: 9.410

7.  Gender and ethnic differences in prevalence of self-reported insomnia among patients with obstructive sleep apnea.

Authors:  Shyam Subramanian; Bharat Guntupalli; Thirumagal Murugan; Swetha Bopparaju; Sreenivas Chanamolu; Lata Casturi; Salim Surani
Journal:  Sleep Breath       Date:  2010-10-16       Impact factor: 2.816

8.  Increased prevalence of sleep-disordered breathing in adults.

Authors:  Paul E Peppard; Terry Young; Jodi H Barnet; Mari Palta; Erika W Hagen; Khin Mae Hla
Journal:  Am J Epidemiol       Date:  2013-04-14       Impact factor: 4.897

9.  Efficacy of Cognitive Behavioral Therapy for Insomnia in Older Adults With Occult Sleep-Disordered Breathing.

Authors:  Constance H Fung; Jennifer L Martin; Karen Josephson; Lavinia Fiorentino; Joseph M Dzierzewski; Stella Jouldjian; Juan Carlos Rodriguez Tapia; Michael N Mitchell; Cathy Alessi
Journal:  Psychosom Med       Date:  2016-06       Impact factor: 4.312

10.  Body mass index, gender, and ethnic variations alter the clinical implications of the epworth sleepiness scale in patients with suspected obstructive sleep apnea.

Authors:  Sean Hesselbacher; Shyam Subramanian; Jerry Allen; Sara Surani; Salim Surani
Journal:  Open Respir Med J       Date:  2012-05-09
View more
  4 in total

1.  Predictive Factors for Obstructive Sleep Apnea Diagnosis in Bariatric Surgery Candidates with or Without Chronic Insomnia Complaints.

Authors:  Ricardo L M Duarte; Flavio J Magalhães-da-Silveira; David Gozal
Journal:  Obes Surg       Date:  2021-10-11       Impact factor: 4.129

Review 2.  More than sleepiness: prevalence and relevance of nonclassical symptoms of obstructive sleep apnea.

Authors:  Johan Verbraecken
Journal:  Curr Opin Pulm Med       Date:  2022-09-14       Impact factor: 2.868

3.  Influence of nocturnal insomnia symptoms on obstructive sleep apnea diagnosis in a clinical referral cohort.

Authors:  Ricardo L M Duarte; Flavio J Magalhães-da-Silveira; David Gozal
Journal:  J Clin Sleep Med       Date:  2022-05-01       Impact factor: 4.324

4.  Restless Legs Syndrome Prevalence and Clinical Correlates Among Psychiatric Inpatients: A Multicenter Study.

Authors:  Franziska C Weber; Heidi Danker-Hopfe; Ezgi Dogan-Sander; Lukas Frase; Anna Hansel; Nicole Mauche; Christian Mikutta; Diana Nemeth; Kneginja Richter; Claudia Schilling; Martina Sebestova; Marian M Spath; Christoph Nissen; Thomas C Wetter
Journal:  Front Psychiatry       Date:  2022-03-14       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.